Roche ($RHHBY) eked out 2% diagnostics sales growth the first half, as the Swiss giant tightened its hold on the immunoassay market but continued to struggle with diabetes and applied science.
However, the long-ailing diabetes care segment continued its slide, dropping 5% on the half thanks to ongoing price pressure and reimbursement challenges for blood glucose monitors, Roche said. But the company isn't standing pat: Roche said it plans to rethink every aspect of its diabetes business, including cost structure, sales, marketing and innovation, so far separating its blood glucose testing business from its insulin pump R&D segment.
Many companies with device aptitude would benefit from VBLOC partnership. Especially those who want to "extract" the clinical benefits of diabetes from it's use! I am anxiously awaiting the PMA acceptance announcement before adding more to my position. Also am eager to begin the next wave of speculation for sales, buyout, partner, etc...Do you know of any reason why FDA would NOT accept the VBLOC submission?
I don't believe failure of a pre-specified, super-superiority endpoint alone justifies a denial...IMO